DURECT Corporation Stock price

Equities

DRRX

US2666055007

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.21 USD -9.70% Intraday chart for DURECT Corporation -3.20% +105.08%
Sales 2023 8.55M Sales 2024 * 10.65M Capitalization 36.09M
Net income 2023 -27M Net income 2024 * -40M EV / Sales 2023 2.06 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 3.39 x
P/E ratio 2023
-0.56 x
P/E ratio 2024 *
-0.95 x
Employees 72
Yield 2023 *
-
Yield 2024 *
-
Free-Float 93.65%
More Fundamentals * Assessed data
Dynamic Chart
1 day-9.70%
1 week-3.20%
Current month+21.00%
1 month+23.47%
3 months+102.71%
6 months-51.01%
Current year+105.08%
More quotes
1 week
1.17
Extreme 1.17
1.34
1 month
0.94
Extreme 0.94
1.44
Current year
0.51
Extreme 0.51
1.44
1 year
0.47
Extreme 0.4703
7.46
3 years
0.47
Extreme 0.4703
20.50
5 years
0.47
Extreme 0.4703
39.49
10 years
0.47
Extreme 0.4703
39.49
More quotes
Managers TitleAgeSince
Founder 67 98-02-05
Director of Finance/CFO 48 22-06-30
Chief Tech/Sci/R&D Officer - 07-12-31
Members of the board TitleAgeSince
Founder 67 98-02-05
Director/Board Member 62 21-12-12
Director/Board Member 68 21-01-03
More insiders
Date Price Change Volume
24-03-28 1.21 -9.70% 234,260
24-03-27 1.34 +5.51% 199,639
24-03-26 1.27 -0.78% 166,781
24-03-25 1.28 +9.40% 85,576
24-03-22 1.17 -6.40% 121,787

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Durect Corporation is a biopharmaceutical company that is focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company's other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The Company is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The Company focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug. CLOUD is a class of bioerodible injectable depot technology.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.21 USD
Average target price
6.75 USD
Spread / Average Target
+457.85%
Consensus
  1. Stock
  2. Equities
  3. Stock DURECT Corporation - Nasdaq